{"id":"NCT01406717","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus","officialTitle":"Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-01","primaryCompletion":"2015-11-04","completion":"2015-11-04","firstPosted":"2011-08-01","resultsPosted":"2019-11-01","lastUpdate":"2020-08-11"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"SPIL1033","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SPIL1033","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"SPIL1033 resembles a gut hormone, which increases the insulin secretion, thus helps in reducing blood glucose levels. The purpose of study is to establish safety and efficacy of SPIL1033","primaryOutcome":{"measure":"Change From Baseline to End of Study in Hemoglobin A1c (HbA1c)","timeFrame":"24 weeks","effectByArm":[{"arm":"SPIL1033","deltaMin":-0.227,"sd":0.243},{"arm":"Placebo","deltaMin":-0.227,"sd":0.254}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":34,"countries":["India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":180},"commonTop":["Hyperglycemia","Nausea","Dyslipidaemia","Hypoglycaemia","Headache"]}}